Oncolytics Retained Earnings vs Capital Stock Analysis

ONCY Stock

USD 1.13 0.03 2.59%

Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Retained Earnings and its Capital Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Retained Earnings vs Capital Stock

Retained Earnings vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Retained Earnings account and Capital Stock. At this time, the significance of the direction appears to have pay attention.

The correlation between Oncolytics Biotech's Retained Earnings and Capital Stock is -0.77. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Retained Earnings and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Oncolytics Biotech are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Retained Earnings i.e., Oncolytics Biotech's Retained Earnings and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.77

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 118.3 M in 2024, whereas Tax Provision is likely to drop slightly above 84.1 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	98.6K	528K	1.2M	1.2M
Net Interest Income	98.6K	528K	1.2M	1.2M

Interest Income Net Interest Income

Oncolytics Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Current Liab	Net Tangible Assets	Common Stock Total Equity	Short Term Investments	Common Stock	Property Plant Equipment	Non Currrent Assets Other
Total Assets		0.14	0.01	0.9	0.74	-0.84	-0.62	-0.07	0.84	-0.13	0.98	-0.15	0.7	0.46	0.66	0.67	0.32	0.45	1.0	0.23	0.68	0.44	0.33	0.66	0.7	0.6
Short Long Term Debt Total	0.14		0.02	-0.1	0.41	-0.02	-0.58	-0.59	0.04	0.01	0.03	0.4	0.48	0.75	0.56	0.55	0.58	0.49	0.14	0.26	0.49	0.56	0.22	0.54	0.53	0.19
Total Current Liabilities	0.01	0.02		-0.3	0.29	0.01	-0.15	0.26	0.0	-0.39	-0.03	0.34	-0.11	0.09	0.16	0.2	0.71	0.37	0.03	0.73	-0.38	0.05	0.11	0.1	0.32	-0.04
Total Stockholder Equity	0.9	-0.1	-0.3		0.51	-0.8	-0.33	0.09	0.82	-0.04	0.94	-0.33	0.48	0.12	0.34	0.38	-0.1	0.1	0.9	-0.11	0.58	0.18	0.17	0.39	0.44	0.58
Property Plant And Equipment Net	0.74	0.41	0.29	0.51		-0.6	-0.75	-0.26	0.64	-0.23	0.7	0.04	0.59	0.59	0.67	0.77	0.64	0.61	0.76	0.38	0.58	0.65	0.37	0.73	0.94	0.51
Net Debt	-0.84	-0.02	0.01	-0.8	-0.6		0.43	0.0	-0.97	0.36	-0.87	0.25	-0.49	-0.27	-0.44	-0.47	-0.13	-0.35	-0.85	-0.21	-0.52	-0.3	-0.07	-0.49	-0.53	-0.27
Retained Earnings	-0.62	-0.58	-0.15	-0.33	-0.75	0.43		0.36	-0.37	0.35	-0.55	-0.11	-0.84	-0.81	-0.84	-0.99	-0.6	-0.69	-0.62	-0.29	-0.78	-0.94	-0.41	-0.99	-0.72	-0.24
Accounts Payable	-0.07	-0.59	0.26	0.09	-0.26	0.0	0.36		0.03	-0.45	0.03	-0.05	-0.51	-0.68	-0.59	-0.27	-0.29	-0.62	-0.03	-0.29	-0.52	-0.44	-0.38	-0.37	-0.27	0.07
Cash	0.84	0.04	0.0	0.82	0.64	-0.97	-0.37	0.03		-0.34	0.87	-0.22	0.38	0.21	0.35	0.42	0.17	0.26	0.86	0.19	0.44	0.22	0.11	0.4	0.58	0.32
Non Current Assets Total	-0.13	0.01	-0.39	-0.04	-0.23	0.36	0.35	-0.45	-0.34		-0.18	-0.14	0.07	0.05	0.07	-0.39	-0.19	0.08	-0.18	-0.09	0.06	-0.29	0.13	-0.31	-0.14	0.28
Cash And Short Term Investments	0.98	0.03	-0.03	0.94	0.7	-0.87	-0.55	0.03	0.87	-0.18		-0.29	0.62	0.34	0.55	0.61	0.21	0.35	0.99	0.15	0.62	0.37	0.28	0.59	0.64	0.57
Net Receivables	-0.15	0.4	0.34	-0.33	0.04	0.25	-0.11	-0.05	-0.22	-0.14	-0.29		-0.1	0.24	0.1	0.13	0.43	0.06	-0.14	0.24	-0.11	0.11	-0.05	0.05	0.06	-0.05
Common Stock Shares Outstanding	0.7	0.48	-0.11	0.48	0.59	-0.49	-0.84	-0.51	0.38	0.07	0.62	-0.1		0.81	0.93	0.82	0.39	0.77	0.67	0.25	0.92	0.79	0.37	0.89	0.62	0.35
Non Current Liabilities Total	0.46	0.75	0.09	0.12	0.59	-0.27	-0.81	-0.68	0.21	0.05	0.34	0.24	0.81		0.9	0.79	0.71	0.78	0.44	0.44	0.69	0.76	0.47	0.8	0.66	0.24
Other Current Assets	0.66	0.56	0.16	0.34	0.67	-0.44	-0.84	-0.59	0.35	0.07	0.55	0.1	0.93	0.9		0.82	0.65	0.9	0.64	0.54	0.78	0.75	0.5	0.86	0.7	0.33
Other Stockholder Equity	0.67	0.55	0.2	0.38	0.77	-0.47	-0.99	-0.27	0.42	-0.39	0.61	0.13	0.82	0.79	0.82		0.64	0.65	0.68	0.31	0.74	0.89	0.38	0.97	0.75	0.31
Total Liab	0.32	0.58	0.71	-0.1	0.64	-0.13	-0.6	-0.29	0.17	-0.19	0.21	0.43	0.39	0.71	0.65	0.64		0.69	0.33	0.74	0.16	0.49	0.44	0.54	0.72	0.19
Property Plant And Equipment Gross	0.45	0.49	0.37	0.1	0.61	-0.35	-0.69	-0.62	0.26	0.08	0.35	0.06	0.77	0.78	0.9	0.65	0.69		0.43	0.72	0.57	0.65	0.35	0.7	0.65	0.12
Total Current Assets	1.0	0.14	0.03	0.9	0.76	-0.85	-0.62	-0.03	0.86	-0.18	0.99	-0.14	0.67	0.44	0.64	0.68	0.33	0.43		0.23	0.66	0.43	0.33	0.66	0.71	0.59
Other Current Liab	0.23	0.26	0.73	-0.11	0.38	-0.21	-0.29	-0.29	0.19	-0.09	0.15	0.24	0.25	0.44	0.54	0.31	0.74	0.72	0.23		0.0	0.13	0.27	0.28	0.42	-0.01
Net Tangible Assets	0.68	0.49	-0.38	0.58	0.58	-0.52	-0.78	-0.52	0.44	0.06	0.62	-0.11	0.92	0.69	0.78	0.74	0.16	0.57	0.66	0.0		0.75	0.32	0.82	0.57	0.39
Common Stock Total Equity	0.44	0.56	0.05	0.18	0.65	-0.3	-0.94	-0.44	0.22	-0.29	0.37	0.11	0.79	0.76	0.75	0.89	0.49	0.65	0.43	0.13	0.75		0.36	0.93	0.6	0.08
Short Term Investments	0.33	0.22	0.11	0.17	0.37	-0.07	-0.41	-0.38	0.11	0.13	0.28	-0.05	0.37	0.47	0.5	0.38	0.44	0.35	0.33	0.27	0.32	0.36		0.39	0.38	0.17
Common Stock	0.66	0.54	0.1	0.39	0.73	-0.49	-0.99	-0.37	0.4	-0.31	0.59	0.05	0.89	0.8	0.86	0.97	0.54	0.7	0.66	0.28	0.82	0.93	0.39		0.69	0.26
Property Plant Equipment	0.7	0.53	0.32	0.44	0.94	-0.53	-0.72	-0.27	0.58	-0.14	0.64	0.06	0.62	0.66	0.7	0.75	0.72	0.65	0.71	0.42	0.57	0.6	0.38	0.69		0.52
Non Currrent Assets Other	0.6	0.19	-0.04	0.58	0.51	-0.27	-0.24	0.07	0.32	0.28	0.57	-0.05	0.35	0.24	0.33	0.31	0.19	0.12	0.59	-0.01	0.39	0.08	0.17	0.26	0.52

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Total Current Liabilities	12.9M	2.7M	2.7M	3.9M	4.2M	3.9M
Total Stockholder Equity	(107.9K)	24.8M	36.1M	26.5M	27.6M	17.8M
Property Plant And Equipment Net	727.5K	609.1K	976.3K	652K	647K	460.6K
Net Debt	(13.6M)	(30.8M)	(40.6M)	(11.3M)	(31.1M)	(29.6M)
Retained Earnings	(344.6M)	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(423.7M)
Accounts Payable	3.2K	1.8K	594K	2.3M	1.1M	1.0M
Cash	14.1M	31.2M	41.3M	11.7M	31.5M	19.3M
Non Current Assets Total	727.5K	609.1K	976.3K	1.7M	647.0K	614.6K
Cash And Short Term Investments	14.1M	31.2M	41.3M	32.1M	34.9M	26.6M
Net Receivables	2.1M	89.7K	866.1K	521K	15K	14.3K
Common Stock Shares Outstanding	22.1M	40.3M	53.5M	58.0M	67.6M	71.0M
Liabilities And Stockholders Equity	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Non Current Liabilities Total	6.9M	6.9M	7.1M	6.9M	7.0M	7.4M
Other Current Assets	2.7M	2.4M	2.8M	3.0M	3.2M	3.4M
Other Stockholder Equity	33.0M	34.6M	37.8M	40.1M	42.1M	38.2M
Total Liab	19.8M	9.6M	9.8M	10.8M	11.3M	6.0M
Property Plant And Equipment Gross	1.7M	609.1K	976.3K	652K	1.3M	1.4M
Total Current Assets	18.9M	33.7M	44.9M	35.7M	38.2M	28.0M
Accumulated Other Comprehensive Income	464.1K	400.2K	387.7K	662K	544K	516.8K
Other Current Liab	12.5M	2.5M	2.4M	1.5M	4.1M	4.3M
Other Liab	4.6M	5.9M	6.7M	6.7M	7.7M	8.1M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	32.0M
Common Stock Total Equity	271.7M	285.2M	311.1M	356.8M	410.3M	430.9M
Short Term Investments	13.1M	30.4M	1.4M	20.5M	3.4M	3.2M
Short Term Debt	339.8K	248.9K	293.7K	216K	133K	127.3K
Common Stock	311.1M	356.8M	391.3M	404.0M	430.9M	452.5M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	377.8K
Capital Lease Obligations	506.3K	402.1K	654.8K	373K	423K	288.3K
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	(107.9K)	24.8M	36.1M	26.5M	27.6M	20.3M
Net Working Capital	6.1M	31.0M	42.2M	31.7M	33.9M	26.6M
Capital Stock	311.1M	356.8M	391.3M	404.0M	430.9M	399.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:

How To Invest In Oncolytics

Details

Is Oncolytics Stock a good investment?

Details

What is Oncolytics Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Oncolytics Stock analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.

	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Is Oncolytics Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.29)

Return On Assets

(0.64)

Return On Equity

(1.16)

The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Retained Earnings vs Capital Stock Analysis

Retained Earnings vs Capital Stock

Retained Earnings vs Capital Stock Correlation Analysis

Correlation Coefficient

Retained Earnings

Capital Stock

Oncolytics Biotech fundamental ratios Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Oncolytics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock	+ 0.97	Other Stockholder Equity
Cash And Short Term Investments	+ 0.94	Total Stockholder Equity
Property Plant Equipment	+ 0.94	Property Plant And Equipment Net

Common Stock	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.97	Net Debt
Common Stock Total Equity	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.85	Net Debt